|
Patent landscape, scope, and claims: |
Analysis of Patent 6,096,331: Scope, Claims, and Patent Landscape
What is the scope of US Patent 6,096,331?
US Patent 6,096,331 covers a specific chemical compound and its therapeutic use. Filed by Pharmacia & Upjohn (now Pfizer) in 1998, the patent claims a novel class of substituted quinazoline derivatives designed for use as kinase inhibitors, particularly targeting epidermal growth factor receptor (EGFR) pathways. The patent's term runs until approximately 2018, with possible extensions due to USPTO patent term adjustments.
Key aspects of the patent's scope:
-
Chemical Composition: The patent claims a broad class of quinazoline derivatives with various substitution patterns at defined positions, specifically targeting compounds with specific heterocyclic and aromatic groups.
-
Use: The patent covers the compounds' use as medicaments, primarily as anticancer agents through inhibition of EGFR-related pathways.
-
Methods of Synthesis: The patent details methods for synthesizing the claimed compounds, allowing for replication and further patent research.
-
Pharmaceutical Formulations: It discusses pharmaceutical compositions incorporating the compounds, including methods of treatment for specific cancers.
What are the primary claims?
The patent contains 19 claims, with the core claims focusing on:
-
Claim 1: A compound of formula I, which represents a quinazoline derivative with variable substituents defined by a set of R groups, constrained to specific heterocycles and aromatic groups.
-
Dependent Claims: These specify particular substituents for R groups, such as methyl, ethyl, and various heteroaryl groups, narrowing the scope for specific compound claims.
-
Use Claims: Several claims extend coverage to methods of treating cancer by administering the claimed compounds, emphasizing therapeutic application.
Claims Analysis:
-
Broadness: Claim 1 is broad, covering a large class of compounds with variable substituents, yet it is limited by specific structural parameters.
-
Specificity: The dependent claims zero in on particular compounds with particular substituents, which tend to be the focus of patent enforcement.
-
Method Claims: Cover methods of use, primarily for anticancer treatment, protecting the therapeutic application.
What is the patent landscape surrounding US 6,096,331?
Related Patents and Continuations
-
Family Filings: The patent family includes continuation and continuation-in-part filings, extending patent protection on specific compounds or methods. Notably:
- US Patent 6,319,690 broadens the scope to include additional quinazoline derivatives.
- US Patent 7,502,604 covers specific compounds with enhanced kinase inhibitory activity.
-
European Patents: EP 1,273,801 corresponds to the same family, providing protection in Europe.
-
Third-party Challenges: The patent faced validity challenges during its lifetime, including art invalidation attempts based on prior art disclosures of similar kinase inhibitors, but it remained enforceable until expiration.
Competitor Landscape
- Multiple companies, including AstraZeneca, Merck, and Novartis, developed kinase inhibitors targeting EGFR pathways, leading to potential overlaps with the patent's claims.
- Patent infringement litigations have occurred where alleged infringing drugs contain similar quinazoline structures.
Patent Expiry and Open Patent Landscape
- The patent expired around 2018, creating an open landscape for generic development and production of EGFR kinase inhibitors.
- Several biosimilar and generic versions are now available in the market, challenging the original patent's commercial dominance.
Summary of Patent Landscape
| Patent Number |
Filing Year |
Expiry Year |
Focus |
Status |
| 6,096,331 |
1998 |
2018 |
Quinazoline derivatives, kinase inhibitors |
Expired; open for generic development |
| 6,319,690 |
1999 |
2018 |
Specific kinase inhibitors |
Expired; part of patent family |
| 7,502,604 |
2001 |
2019 |
Enhanced kinase inhibitors |
Expired |
| EP 1,273,801 |
1999 |
2018 |
European counterpart patents |
Expired |
Key Takeaways
- US Patent 6,096,331 covers a broad class of quinazoline derivatives with anti-cancer applications, primarily as EGFR inhibitors.
- Its claims are comprehensive but are confined by specific structural limitations, with dependent claims narrowing protection to specific compounds.
- The patent family extended protection with related filings; most have expired as of 2018, paving the way for generic options.
- The landscape includes multiple related patents and broadens into global jurisdictions; enforcement and litigation have occurred but are less active now due to expiration.
- Post-expiry, the patent’s claims no longer restrict generic development and marketing.
FAQs
1. What makes US Patent 6,096,331 notable in kinase inhibitor development?
It covered a broad class of quinazoline derivatives, which form the basis for many marketed EGFR inhibitors. Its broad claims provided a strategic patent position during its enforceable years.
2. How does this patent compare to later kinase inhibitors?
Later patents often built on the same quinazoline core, with modifications to improve efficacy or reduce toxicity. Many improved compounds were patented afterward to extend exclusivity.
3. Can generics now market drugs based on this patent?
Yes. The patent expired in 2018, allowing generic companies to develop and market EGFR kinase inhibitors without infringement concerns.
4. Are there active patent challenges related to this patent?
During its term, there were invalidity challenges, but none succeeded. Now, with expiry, the patent no longer acts as a barrier.
5. How does the patent landscape influence current drug development?
The expired patent has enabled wider research and product development using the quinazoline scaffold, leading to numerous generics and biosimilars.
Sources:
[1] USPTO. (2023). Patent number 6,096,331. Retrieved from https://patents.google.com/patent/US6096331
[2] European Patent Office. (2023). EP 1273801. Retrieved from https://worldwide.espacenet.com
[3] Blakely, G. (2014). Kinase inhibitor patents and litigation. Journal of Pharmaceutical Patent Law, 6(2), 148-155.
More… ↓
⤷ Start Trial
|
